Results 281 to 290 of about 103,858 (377)

Understanding erythroid physiology and pathology in humanized mice: A closer look

British Journal of Haematology, EarlyView.
Erythropoiesis, the formation of red blood cells (RBCs) from haematopoietic stem cells (HSCs), is vital for understanding conditions like anaemia and haemoglobinopathies. However, studying this process in vivo is challenging due to the lack of accurate models.
Lu Lu, Chenfei Liu, Lezong Chen, Xumiao Zhang, Yinglin Su, Zhenzhen Chou, Yang Liang, Yuanbin Song   +7 more
wiley   +1 more source

How low can we go? Comparison of liberal and restrictive red cell transfusion thresholds in paediatric allogeneic haematopoietic stem cell transplantation: A randomized multicentre feasibility trial

British Journal of Haematology, EarlyView.
Optimal red blood cell transfusion thresholds for children with bone marrow failure are uncertain. Children may be able to safely tolerate lower haemoglobin thresholds, thereby reducing transfusions, which have risks. This study in paediatric allogeneic haematopoietic stem cell transplant aimed to assess feasibility of recruitment and protocol ...
H. V. New, E. Sanderson, V. Hopkins, H. Thomas, A. Gassas, M. Adams, B. Gibson, K. Patrick, R. Wynn, L. Hoole, H. Smethurst, M. Lobo‐Clarke, L. Smith, A. Mora, S. J. Stanworth   +14 more
wiley   +1 more source

Platelet transfusion practices among neonatologists in Saudi Arabia: A nationwide cross-sectional survey. [PDF]

Medicine (Baltimore)
Al-Shehri H, Almohandes AM, Alanazi D, Bin Shlhoob R, Alsenidi SF, Busaid NF, Jabari M, Alzayed A, Elabbasy A, Naser AY.   +9 more
europepmc   +1 more source

The wider perspective: Barriers and recommendations for transfusion support for patients with sickle cell disease in low‐ and middle‐income countries

British Journal of Haematology, EarlyView.
Globally, sickle cell disease (SCD) is the most common inherited haemoglobinopathy. The highest burden of SCD is encountered in low‐ and middle‐income countries (LMICs), most of which lack the resources to contend with the disease. Blood transfusion remains central to the emergent treatment and prevention of complications of SCD.
Jeremy W. Jacobs, Luiz Amorim, France Pirenne, Claude Tayou, Ijele Adimora, Lydia H. Pecker, Aaron A. R. Tobian, Jeannie Callum, Julie Makani, Mark T. Gladwin, Meghan Delaney, Darrell J. Triulzi, Isaac Odame, Evan M. Bloch   +13 more
wiley   +1 more source

Evaluation of an appropriate size of unrelated donor pool for HLA-matched platelet transfusion and bone marrow transplantation.

, 1992
Kenji Takahashi, Takeo Juji, Katsushi Tokunaga, Chieko Uchikawa, Tatsuya Akaza, Kazuo Umezawa, N Endoh, H. Kamata, H. Tsuchida, Kimihiro Fujino, Ichiro Watanabe   +10 more
openalex   +2 more sources

Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single‐centre experience

British Journal of Haematology, EarlyView.
Summary There is still no standard of care and unmet medical needs in refractory/advanced VEXAS (vacuoles in myeloid progenitors, E1 ubiquitin activating enzyme, X‐linked, autoinflammatory manifestations and somatic) syndrome with or without associated haematological neoplasm.
Maël Heiblig, Adriana Plesa, Juliet Tantot, Yvan Jamilloux, Hélène Labussière‐Wallet, Pierre Sujobert   +5 more
wiley   +1 more source

Transfusion of fresh whole blood stored (4° C) for short period fails to improve platelet aggregation on extracellular matrix and clinical hemostasis after cardiopulmonary bypass

, 1990
Michael Golan, Michaela Modan, Jacob Lavee, U. Martinowitz, Naphtali Savion, Daniel A. Goor, Rephael Mohr   +6 more
openalex   +1 more source

Platelet transfusion enhances pro-aggregatory status shortly after coronary artery bypass grafting (CABG while modulating platelet pro-inflammatory state 1-week post-surgery. [PDF]

J Cell Mol Med
Ahmadi J, Hosseini E, Kargar F, Maghsudlu M, Ghasemzadeh M.   +4 more
europepmc   +1 more source

Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma

European Journal of Haematology, EarlyView.
ABSTRACT Objective Melphalan flufenamide (melflufen) plus dexamethasone is fully approved in Europe for patients with relapsed/refractory multiple myeloma (RRMM) with ≥ 3 prior lines of therapy. We analyzed the efficacy and safety of melflufen in the real‐world setting.
Shahrier Hossain, Clifton Mo, Sarah Patches, Houry Leblebjian, Kathryn Goodrich, Eileen Regan, Kathleen O'Neill, Kim Noonan, Paul G. Richardson, Jacob Laubach   +9 more
wiley   +1 more source

Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria

European Journal of Haematology, EarlyView.
ABSTRACT Background Paroxysmal nocturnal haemoglobinuria (PNH) is an ultra‐rare, acquired non‐malignant haematological disorder characterised by thrombosis risk, serious complications and debilitating symptoms in untreated patients. Objective This anchored indirect treatment comparison (ITC) evaluated efficacy data between proximal complement 3 ...
Regis Peffault de Latour, Austin Kulasekararaj, David Dingli, Koo Wilson, Piotr Wojciechowski, Zalmai Hakimi, Jameel Nazir, Barbara Czech, Peter Hillmen, Jeff Szer   +9 more
wiley   +1 more source